CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 341 enrolled
Drug / intervention
TAK-536TCH tablet +2 moredrug
Likely dose
HCTZ 12.5 mg tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02277691
NCT02277691Phase 3Completed
CompareCT.gov

A Phase 3, Open-label, Multicenter, Long-term Study to Evaluate the Safety and Efficacy of TAK-536, Amlodipine and Hydrochlorothiazide in Subjects With Essential Hypertension

Takeda·interventional·Posted Oct 29, 2014·Updated Aug 2, 2017

In Brief

A Phase 3 clinical trial evaluating TAK-536TCH tablet, TAK-536CCB tablet, and 1 other intervention for Essential Hypertension. Completed, enrolled 341 participants across 38 sites.

Detailed Summary

The purpose of this study is to evaluate the safety of long-term administration of TAK-536, amlodipine (AML), and hydrochlorothiazide (HCTZ) in participants with essential hypertension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Hypertension
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 29, 2014
Enrollment StartNov 7, 2014
Primary CompletionApr 25, 2016
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11.7 years ago

Interventions

TAK-536TCH tabletdrug

TAK-536TCH tablets

TAK-536CCB tabletdrug

TAK-536CCB tablets

HCTZ 12.5 mg tabletdrug

HCTZ tablets